Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience-Reference-Cited by-同舟云学术

Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience

Published:2018-02-21 Issue:11 Volume:59 Page:2737-2739
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Al-Kali Aref¹^ORCID,Abou Hussein Ahmed Kamel¹,Patnaik Mrinal¹^ORCID,Zblewski Darci¹,Gangat Naseema¹,Hashmi Shahrukh¹,Elliott Michelle¹,Hogan William¹^ORCID,Litzow Mark¹^ORCID

Affiliation:

1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1436705

Reference12 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

2. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation

3. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

4. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations

5. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN;Leukemia Research;2024-07

2. Adrenal infarction with latent myelodysplastic/myeloproliferative neoplasm, unclassifiable with JAK2V617F mutation;Clinical Case Reports;2024-04

3. Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy;Leukemia & Lymphoma;2022-04-04

4. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group;Modern Pathology;2021-11-13

5. Pathogenic Mutations and Atypical Flow Cytometric Findings Characterize the Majority of Unclassifiable Myelodysplastic/Myeloproliferative Neoplasms;American Journal of Clinical Pathology;2021-04-20